EORTC research on the Gastrointestinal tract focuses on expanding what we know about the genetic, epigenetic and immunologic backgrounds of gastrointestinal tumour diseases. Clinical trials in this field focus on preclinical to clinical interaction and integrating early drug development, ensuring that new aspects of tumour biology are being investigated with appropriate contemporary technology.
The mission of the GI group is to develop therapeutic strategies through innovative studies, which are multidisciplinary, patient-centered and have a strong translational focus. It responds to the evolving landscape of cancer research by expanding its collaboration with different cancer research networks from Europe and Asia, enriching its pool of multidisciplinary experts and redesigning its young investigator’s program to enable future leaders to be at the forefront of GI cancer research.
Related NewsAll news
Assessment of a potential new treatment option for patients with metastatic gastrointestinal stromal tumor (GIST) that may overcome resistance to established compounds
Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
DREAM: Diffusion-Weighted Magnetic REsonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning
Protocol SAKK 41/13 Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial
Phase II of immunotherapy plus local tumour ablation (RFA or stereotactic radiotherapy) in patients with colorectal cancer liver metastases
Published joint Clinical Practice Guidelines on the management of hepatocellular carcinoma with the European Association for the Study of the Liver (EASL) ; . These define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.
The CLOCC randomised controlled phase II study performed in patients with liver metastases from colorectal cancer suggests that radiofrequency ablation of liver lesions prolongs survival . Based on these findings, the group is now starting a study combining this approach with immunotherapy (ILOC study).
Long-term follow up data in the EPOC randomised controlled phase III study confirm the significant improvement in progression-free survival of perioperative chemotherapy in resectable liver metastases from colorectal cancer.
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
University Cancer Center Leipzig
Cambridge University Hospital NHS - Addenbrookes Hospital
Cambridge, United Kingdom
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Task Force - Colon
M. Peeters - Antwerp, BE
Universitair Ziekenhuis Antwerpen
T. Kössler - Geneve, CH
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie
F. Sclafani - Brussels, BE
Institut Jules Bordet-Hopital Universitaire ULB
Task Force - Rectum, Anal canal
D. Arnold - Lisbon, PT
Hospital CUF Infante Santo
L. Wyrwicz - Warsaw, PL
Maria Sklodowska-Curie Memoral Cancer Center
Task Force - Esophagus and Stomach
M. Moehler - Mainz, DE
Johannes Gutenberg Universitaetskliniken Mainz University Medical Center
A. Wagner - Lausanne, CH
Centre Hospitalier Universitaire Vaudois
Task Force - Hepatobiliary, Pancreas and NETs
J. Valle - Manchester, GB
The Christie NHS Foundation Trust
J. Ricke - Munich, DE
Kliniken Der Universitaet Muenchen
Task Force - Translational Research
H. Grabsch - Maastricht, NL
Academisch Ziekenhuis Maastricht
Task Force - SPECTA and early phase trials
R. Obermannova - Brno, CZ
Masaryk Memorial Cancer Institute
M. Alsina - Barcelona, ES
Vall d'Hebron Institut d'oncologia
Task Force - Adolescents and Young Adults
I. Ben-Aharon - Tel Aviv, IL
Rabin Medical Center - Tel Aviv University
Task Force - Newsletters
J. Freire - Lisbon, PT
I.P.O. Francisco Gentil - Centro de Lisboa
Task Force - St. Gallen Meetings & Membership
M. Lutz - Saarbrucken, DE
Caritasklinik St. Theresa
Task Force - Young Investigator Program
A. Roth - Geneva, CH
Hopitaux Universitaire de Genève - HUG - Site de Cluse Roseraie
R. Salazar - Barcelona, ES
Institut Catala d'Oncologia
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER-2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC- GI-group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB Study : a propective liver metastasis database with an integrated Quality Assurance program
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).